Nadja West Sells 809 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Nadja West sold 809 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $51.11, for a total transaction of $41,347.99. Following the completion of the sale, the director now owns 37,705 shares in the company, valued at $1,927,102.55. The trade was a 2.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Tempus AI Price Performance

Shares of Tempus AI stock opened at $49.10 on Friday. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The company’s fifty day moving average is $54.30 and its two-hundred day moving average is $52.44.

Wall Street Analysts Forecast Growth

TEM has been the topic of a number of analyst reports. Needham & Company LLC raised their price objective on shares of Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Bank of America lifted their price target on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Morgan Stanley lifted their price target on shares of Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday. Loop Capital cut their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Finally, TD Cowen reiterated a “buy” rating and set a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.18.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $108,000. Voloridge Investment Management LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $11,826,000. Two Sigma Advisers LP purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $625,000. ProShare Advisors LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $244,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $1,034,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.